Data gathered: November 14
Alternative Data for Oragenics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 5 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 41,820 | Sign up | Sign up | Sign up |
| Twitter Mentions | 100 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 18 | Sign up | Sign up | Sign up |
About Oragenics
Oragenics, Inc. develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
| Price | $0.35 |
| Target Price | Sign up |
| Volume | 57,730 |
| Market Cap | $4.1M |
| Year Range | $0.3 - $3.07 |
| Dividend Yield | 0% |
| Analyst Rating | 0% buy |
| Industry | Biotechnology |
In the news
 |
Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.comOctober 28 - ETF Daily News |
|
StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)October 18 - ETF Daily News |
 |
Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas SummitOctober 18 - Investing.com |
Oragenics Shares Investor Presentation OnlineOctober 15 - TipRanks |
|
|
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)October 12 - ETF Daily News |
|
Oragenics (NYSE:OGEN) Files Form 8-K with SEC Disclosing Material ChangeOctober 10 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 1.6M | -1.6M | -2.5M | -2.4M | 0.000 |
| Q2 '24 | 0 | 1.4M | -1.4M | -2.3M | -2.3M | -0.509 |
| Q1 '24 | 0 | 1.8M | -1.8M | -2.5M | -2.4M | -0.701 |
| Q4 '23 | -38,000 | 1.8M | -1.8M | -13M | -13M | -4.138 |
| Q3 '23 | 16,000 | 1.3M | -1.3M | -2M | -2.1M | -0.854 |
Insider Transactions View All
| Telling Fred filed to sell 38,345 shares at $3.6. December 1 '23 |
| KOSKI ROBERT C filed to sell 1,102,295 shares at $0.1. January 3 '23 |
| KOSKI ROBERT C filed to sell 176,191 shares at $0.1. January 3 '23 |
| KOSKI ROBERT C filed to sell 1,144,652 shares at $0.2. December 16 '22 |
| KOSKI ROBERT C filed to sell 1,310,149 shares at $0.2. December 15 '22 |
Similar companies
Read more about Oragenics (OGEN) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of Oragenics?
The Market Cap of Oragenics is $4.1M.
What is the current stock price of Oragenics?
Currently, the price of one share of Oragenics stock is $0.35.
How can I analyze the OGEN stock price chart for investment decisions?
The OGEN stock price chart above provides a comprehensive visual representation of Oragenics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Oragenics shares. Our platform offers an up-to-date OGEN stock price chart, along with technical data analysis and alternative data insights.
Does OGEN offer dividends to its shareholders?
As of our latest update, Oragenics (OGEN) does not offer dividends to its shareholders. Investors interested in Oragenics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Oragenics?
Some of the similar stocks of Oragenics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.